Almirall's aclidinium adventure continues with EU approval
This article was originally published in Scrip
The European Commission has granted Almirall's aclidinium bromide product approval in all EU member states, plus Iceland and Norway. The approval was expected after the CHMP gave the drug a positive opinion in May covering use as a maintenance bronchodilator treatment to relieve symptoms in patients with COPD (scripintelligence.com, 25 May 2012). US approval too is expected in July.